Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris

Table 3

Lipid markers and atherogenic indexes in statin-treated and non-statin-treated IHD patients.

	SAP(+)	SAP(−)	USAP(+)	USAP(−)	STEMI(+)	STEMI(−)	Controls
TG (mmol/L)	1.69 (0.93–8.68)	1.98 (0.38–8.68)	1.9 (0.88–6.14)	2.0 (0.56–7.56)	1.9 (0.37–4.96)	1.9 (0.56–4.31)	1.4 (0.46–4.18)
Tc (mmol/L)	5.38 ± 1.25	5.76 ± 2.09	5.87 ± 1.57	5.82 ± 1.22	5.90 ± 1.63	5.72 ± 1.17	5.48 ± 0.49
HDL-c (mmol/L)	1.20 ± 0.29	1.17 ± 0.31	1.02±0.27^∗	1.19 ± 0.30	1.05 ± 0.25	1.16 ± 0.28	1.15 ± 0.28
LDL-c (mmol/L)	3.26 ± 1.11	3.28 ± 1.08	3.67±1.40	3.66 ± 1.01	3.85 ± 1.38	3.66 ± 1.01	3.51 ± 0.59
Lp(a) (mg/dL)	16.7 (4.0–68.0)	12.6 (7.0–22.0)	22.3 (5.9–59.7)	25.0 (20.4–36.6)	15.2 (5.0–64.0)	20.1 (14.0–37.2)	5.6 (2.9–19.7)
ApoA-I	1.28±0.39^∗	1.46 ± 0.30	1.13±0.33^∗	1.41 ± 0.33	1.12±0.17^∗∗	1.44 ± 0.31	1.34 ± 0.21
Apo B (g/L)	0.98 ± 0.36	1.04 ± 0.26	1.18 ± 0.39	1.09 ± 0.22	1.25±0.33^∗	1.11 ± 0.22	1.17 ± 0.14
oxLDL (ng/mL)	210 (12–1925)	230 (20–498)	153 (7–1550)	125 (42–657)	152 (15–2150)	72 (30–541)	195 (18–705)
TG/apoB	1.66 (0.67–3.42)	1.98 (0.67–5.32)	1.90 (0.69–4.73)	1.80 (0.41–5.52)	1.60 (0.71–4.07)	1.70 (0.68–5.07)	1.17 (0.68–1.91)
apoA/apoB	0.78 (0.27–1.66)	0.80 (0.39–1.33)	1.08 (0.45-1.99)^∗∗	0.77 (0.42–1.59)	1.10(0.43-1.79)^∗∗	0.80 (0.25–1.55)	0.91 (0.41–0.56)
TG/HDL-c	1.51 (0.25–10.21)	1.62 (0.25–5.23)	3.70 (1.79-6.55)^∗	1.70 (0.40–9.33)	2.10 (0.66–5.90)	1.70 (0.54–5.60)	0.87 (0.24–2.73)
LDL-c/HDL-c	2.55 (0.85–6.58)	2.79 (1.21–4.69)	3.70 (1.79–6.55)	3.00 (1.72–4.71)	3.50 (1.35-6.45)^∗	3.20 (0.77–5.53)	2.47 (1.17–3.76)
Tc/HDL-c	4.52 (2.25–8.76)	4.92 (2.32–10.41)	5.90 (3.22-11.00)^∗	5.00 (3.10–8.80)	5.70 (2.65-9.18)^∗	5.10 (2.42–8.13)	4.44 (2.27–6.97)
LDL-c/apoB	3.22 (1.58–4.04)	3.01 (1.58–3.87)	3.10 (1.86-3.85)^∗	3.40 (2.10–4.05)	3.10 (1.60-3.98)^∗	3.40 (1.98–4.04)	3.40 (2.04–3.96)

The results are presented as means ± SD for parametric, and mediana (min–max) for nonparametric values ^∗𝑃<.05 versus (−) group, ^∗∗𝑃<.001 versus (−) group.